Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1980 Nov;43(11):978–985. doi: 10.1136/jnnp.43.11.978

Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine.

D B Sanders, Y I Kim, J F Howard Jr, C A Goetsch
PMCID: PMC490748  PMID: 6255102

Abstract

In a patient with the Eaton-Lambert syndrome, 4-aminopyridine produced temporary improvement of clinical and electromyographic abnormalities. Application of the drug in vitro to intercostal muscle from the patient produced an increase in the evoked release of neurotransmitter from intramuscular nerves.

Full text

PDF
978

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agoston S., van Weerden T., Westra P., Broekert A. Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br J Anaesth. 1978 Apr;50(4):383–385. doi: 10.1093/bja/50.4.383. [DOI] [PubMed] [Google Scholar]
  2. Albuquerque E. X., Rash J. E., Mayer R. F., Satterfield J. R. An electrophysiological and morphological study of the neuromuscular junction in patients with myasthenia gravis. Exp Neurol. 1976 Jun;51(3):536–563. doi: 10.1016/0014-4886(76)90179-5. [DOI] [PubMed] [Google Scholar]
  3. Borenstein S., Desmedt J. E. Local cooling in myasthenia. Improvement of neuromuscular failure. Arch Neurol. 1975 Mar;32(3):152–157. doi: 10.1001/archneur.1975.00490450032003. [DOI] [PubMed] [Google Scholar]
  4. Brown J. C., Johns R. J. Diagnostic difficulties encountered in the myasthenic syndrome sometimes associated with carcinoma. J Neurol Neurosurg Psychiatry. 1974 Nov;37(11):1214–1224. doi: 10.1136/jnnp.37.11.1214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cherington M. Guanidine and germine in Eaton-Lambert syndrome. Neurology. 1976 Oct;26(10):944–946. doi: 10.1212/wnl.26.10.944. [DOI] [PubMed] [Google Scholar]
  6. Cull-Candy S. G., Lundh H., Thesleff S. Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol. 1976 Aug;260(1):177–203. doi: 10.1113/jphysiol.1976.sp011510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. EATON L. M., LAMBERT E. H. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. J Am Med Assoc. 1957 Mar 30;163(13):1117–1124. doi: 10.1001/jama.1957.02970480021005. [DOI] [PubMed] [Google Scholar]
  8. ELMQVIST D., JOHNS T. R., THESLEFF S. A study of some electrophysiological properties of human intercostal muscle. J Physiol. 1960 Dec;154:602–607. doi: 10.1113/jphysiol.1960.sp006599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Elmqvist D., Lambert E. H. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin Proc. 1968 Oct;43(10):689–713. [PubMed] [Google Scholar]
  10. Elmqvist D., Quastel D. M. A quantitative study of end-plate potentials in isolated human muscle. J Physiol. 1965 Jun;178(3):505–529. doi: 10.1113/jphysiol.1965.sp007639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Harvey A. L., Marshall I. G. The actions of three diaminopyridines on the chick biventer cervicis muscle. Eur J Pharmacol. 1977 Aug 15;44(4):303–309. doi: 10.1016/0014-2999(77)90303-x. [DOI] [PubMed] [Google Scholar]
  12. Ishikawa K., Engelhardt J. K., Fujisawa T., Okamoto T., Katsuki H. A neuromuscular transmission block produced by a cancer tissue extract derived from a patient with the myasthenic syndrome. Neurology. 1977 Feb;27(2):140–143. doi: 10.1212/wnl.27.2.141. [DOI] [PubMed] [Google Scholar]
  13. Kim Y. I., Goldner M. M., Sanders D. B. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve. 1980 Mar-Apr;3(2):112–119. doi: 10.1002/mus.880030203. [DOI] [PubMed] [Google Scholar]
  14. Kim Y. I., Goldner M. M., Sanders D. B. Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission. Muscle Nerve. 1980 Mar-Apr;3(2):105–111. doi: 10.1002/mus.880030202. [DOI] [PubMed] [Google Scholar]
  15. LILEY A. W. The quantal components of the mammalian end-plate potential. J Physiol. 1956 Sep 27;133(3):571–587. doi: 10.1113/jphysiol.1956.sp005610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lambert E. H. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann N Y Acad Sci. 1966 Jan 26;135(1):367–384. doi: 10.1111/j.1749-6632.1966.tb45484.x. [DOI] [PubMed] [Google Scholar]
  17. Lambert E. H., Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci. 1971 Sep 15;183:183–199. doi: 10.1111/j.1749-6632.1971.tb30750.x. [DOI] [PubMed] [Google Scholar]
  18. Lambert E. H., Lindstrom J. M., Lennon V. A. End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci. 1976;274:300–318. doi: 10.1111/j.1749-6632.1976.tb47694.x. [DOI] [PubMed] [Google Scholar]
  19. Lundh H., Leander S., Thesleff S. Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine. J Neurol Sci. 1977 May;32(1):29–43. doi: 10.1016/0022-510x(77)90037-5. [DOI] [PubMed] [Google Scholar]
  20. Lundh H., Nilsson O., Rosén I. 4-aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry. 1977 Nov;40(11):1109–1112. doi: 10.1136/jnnp.40.11.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lundh H., Nilsson O., Rosén I. Effects of 4-aminopyridine in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1979 Feb;42(2):171–175. doi: 10.1136/jnnp.42.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. MARTIN A. R. A further study of the statistical composition on the end-plate potential. J Physiol. 1955 Oct 28;130(1):114–122. doi: 10.1113/jphysiol.1955.sp005397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McQuillen M. P., Johns R. J. The nature of the defect in the Eaton-Lambert syndrome. Neurology. 1967 Jun;17(6):527–536. doi: 10.1212/wnl.17.6.527. [DOI] [PubMed] [Google Scholar]
  24. Norris F. H., Jr, Calanchini P. R., Fallat R. J., Panchari S., Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974 Aug;24(8):721–728. doi: 10.1212/wnl.24.8.721. [DOI] [PubMed] [Google Scholar]
  25. Norris F. H., Jr, Eaton J. M., Mielke C. H., Jr Depression of bone marrow by guanidine. Arch Neurol. 1974 Feb;30(2):184–185. doi: 10.1001/archneur.1974.00490320072012. [DOI] [PubMed] [Google Scholar]
  26. O S. J., Kim K. W. Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement. Neurology. 1973 Oct;23(10):1084–1090. doi: 10.1212/wnl.23.10.1084. [DOI] [PubMed] [Google Scholar]
  27. Ward C. D., Murray N. M. Effect of temperature on neuromuscular transmission in the Eaton-Lambert syndrome. J Neurol Neurosurg Psychiatry. 1979 Mar;42(3):247–249. doi: 10.1136/jnnp.42.3.247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yeh J. Z., Oxford G. S., Wu C. H., Narahashi T. Dynamics of aminopyridine block of potassium channels in squid axon membrane. J Gen Physiol. 1976 Nov;68(5):519–535. doi: 10.1085/jgp.68.5.519. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES